Theoretical Pharmacological Rationale for Benzphetamine in ADHD Treatment During Stimulant Shortage

This editorial explores whether benzphetamine, an FDA-approved obesity medication that metabolizes into dextroamphetamine and dextromethamphetamine, could theoretically help address the current shortage of ADHD stimulant treatments. The authors acknowledge significant limitations due to absence of ADHD-specific benzphetamine data and deliberately avoid making clinical claims or treatment recommendations.